News & Updates

Is extended superior to standard antibiotic course in children hospitalized with CAP?

11 Jul 2022

An extended antibiotic course appears to be not any better than a standard course at achieving clinical cure among children hospitalized with community-acquired pneumonia (CAP) and at risk of chronic respiratory illnesses at 4 weeks, a study has shown.

Is extended superior to standard antibiotic course in children hospitalized with CAP?

11 Jul 2022

BMD gains in postmenopausal osteoporosis more favourable with denosumab vs ibandronate

11 Jul 2022

Denosumab proves better than ibandronate as a sequential therapy in women with postmenopausal osteoporosis who have received romosozumab, as the former yields greater improvements in bone mineral density (BMD) with few severe adverse events, according to the results of the VICTOR study.

BMD gains in postmenopausal osteoporosis more favourable with denosumab vs ibandronate

11 Jul 2022

Triheptanoin for seizure reduction disappoints in patients with Glut1DS

11 Jul 2022

Treatment with triheptanoin does not lead to a significant reduction in the frequency of seizures associated with glucose transporter 1 deficiency syndrome (Glut1DS), as shown in a study.

Triheptanoin for seizure reduction disappoints in patients with Glut1DS

11 Jul 2022

Are biologic agents of any help in treating mucous membrane pemphigoid?

10 Jul 2022

Biologic treatments are effective in the treatment of mucous membrane pemphigoid (MMP), with a good safety profile, except for rituximab, a study has found. However, randomized clinical trials with long-term follow-up are warranted to confirm the safety and efficacy of these agents in MMP patients.

Are biologic agents of any help in treating mucous membrane pemphigoid?

10 Jul 2022

Sabizabulin for metastatic castration-resistant prostate cancer clears phase early trial

10 Jul 2022

The oral cytoskeleton disruptor sabizabulin shows antitumour activity in men with metastatic castration-resistant prostate cancer, while having a favourable safety profile, as shown in the results of a phase Ib/II trial.

Sabizabulin for metastatic castration-resistant prostate cancer clears phase early trial

10 Jul 2022

Delgocitinib ointment beneficial in chronic hand eczema

09 Jul 2022

The pan-Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation is well tolerated and demonstrates a dose-response effect in the treatment of patients with chronic hand eczema, according to the results of a phase IIb trial.

Delgocitinib ointment beneficial in chronic hand eczema

09 Jul 2022

Dutasteride shows promise for chronic prostatitis

09 Jul 2022

Dutasteride treatment leads to a significant reduction in chronic prostatitis symptom scores in patients with category IIIB disease, a new study has found.

Dutasteride shows promise for chronic prostatitis

09 Jul 2022

Quizartinib bounces back, doubles OS in FLT3-ITD-positive AML

09 Jul 2022 by

The oral FLT3 inhibitor quizartinib more than doubled overall survival (OS) when added to first-line chemotherapy in patients with newly diagnosed FLT3-ITD*-positive acute myeloid leukaemia (AML) in the phase III QuANTUM-First** trial